Lapatinib Completed Phase 2 Trials for Adenocarcinomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00259987Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus